Entities / Person
Mash.
Japanese singer-songwriter
- Reports this week
- 1
- Active events
- 0
- Connections
- 19
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Madrigal Pharmaceuticals received FDA approval for its drug Rezdiffra, which targets MASH. The company also participated in a conference hosted by Morgan Stanley.Well supported11 reports
-
Madrigal Pharmaceuticals entered an exclusive global license agreement for SYH2086, a potential best-in-class MASH treatment.Some support1 report
-
Altimmune, Inc. appointed Jerry Durso as Chairman of the board while developing therapeutics for MASH.Some support3 reports
-
Madrigal Pharmaceuticals' Rezdiffra received authorization for MASH from the European Commission, prompting analyst price target increases.Some support6 reports
-
89bio is developing therapies for MASH, and the company's operations are subject to the requirements of Nasdaq Listing Rule 5635(c).Some support1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 4 strongest of 19, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Can-Fite BioPharma (Israel) Operational
Can-Fite BioPharma is developing and evaluating Namodenoson as a treatment for the MASH indication.
-
Altimmune, Inc. Mentioned together
Both entities are mentioned in the context of developing therapeutics for MASH.
-
Elias Zerhouni Structural
Mash and Elias Zerhouni co-founded the company ModeX.
-
Madrigal Pharmaceuticals (United States) Mentioned together
No evidence was found in the timeline linking Madrigal Pharmaceuticals and Mash.
History
Events by the month they beganJune 2026
5 events- Madrigal Pharmaceuticals received FDA approval for its drug Rezdiffra, which targets MASH. The company also participated in a conference hosted by Morgan Stanley.
- Madrigal Pharmaceuticals entered an exclusive global license agreement for SYH2086, a potential best-in-class MASH treatment.
- Altimmune, Inc. appointed Jerry Durso as Chairman of the board while developing therapeutics for MASH.
- Madrigal Pharmaceuticals' Rezdiffra received authorization for MASH from the European Commission, prompting analyst price target increases.
- 89bio is developing therapies for MASH, and the company's operations are subject to the requirements of Nasdaq Listing Rule 5635(c).